Table 2. Adherence to anti-TB drugs in intensive and continuation phase (N = 645).

Cohort (N intensive/N continuation)	Intensive			Continuation
	Adherent n (%)	90% CI	p-value*	Adherentn (%)	90% CI	p-value*	p-value**
Overall (320/325)	306 (95.6)	93.4–97.5	<0.001	311 (95.7)	93.8–97.5	<0.001	0.967
Urban (161/158)	154 (95.7)	93.0–98.3	<0.001	154 (97.5)	95.4–99.5	<0.001	0.374
Rural (159/167)	152 (95.6)	92.9–98.3	<0.001	157 (94.0)	90.9–97.0	<0.001	0.519
Pilot (160/160)	158 (98.8)	97.3–100.2	<0.001	158 (98.8)	97.3–100.2	<0.001	1.000
Non-pilot (160/165)	148 (92.5)	89.1–95.9	<0.001	153 (92.7)	89.4–96.1	<0.001	0.938

^*Comparison with hypothesis value of 75% (1-sided 90%CI).

^**Comparison between intensive and versus continuation phases (2-sided 95%CI).